SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Allogene Therapeutics Inc. (ALLO) on Wednesday reported a loss of $42.7 million in its second quarter.

The South San Francisco, California-based company said it had a loss of 13 cents per share.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 16 cents per share.

The immuno-oncology company posted revenue of $4.5 million in the period.

In the final minutes of trading on Wednesday, the company's shares hit $2.08. A year ago, they were trading at $1.03.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALLO at https://www.zacks.com/ap/ALLO